08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

AN2898: Preliminary Phase IIa data

Preliminary data from a double-blind, Australian Phase IIa trial in 46 patients with mild to moderate atopic dermatitis showed that topical twice-daily 2% AN2728 and twice-daily 1% AN2898 for 6 weeks each met the...
08:00 , Dec 19, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) gained $0.15 (24%) to $0.78 on Tuesday after FDA's Psychopharmacologic Drugs Advisory Committee voted 9-8, with one abstention, in favor of recommending approval of inhaled Adasuve loxapine to treat agitation...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

AN2728: Preliminary Phase IIa data

Preliminary data from a double-blind, Australian Phase IIa trial in 46 patients with mild to moderate atopic dermatitis showed that topical, twice-daily 2% AN2728 and twice-daily 1% AN2898 for 6 weeks each met the...
02:44 , Dec 14, 2011 |  BC Extra  |  Clinical News

Anacor compounds meet atopic dermatitis endpoints

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) said topical twice-daily 2% AN2728 and twice-daily 1% AN2898 for six weeks each met the primary endpoint in a Phase IIa trial to treat atopic dermatitis. AN2728 and AN2898 each led...
07:00 , May 23, 2011 |  BC Week In Review  |  Clinical News

AN2728: Phase II started

Anacor began a double-blind, vehicle-controlled, Australian Phase II trial to evaluate topical 1% AN2898 twice daily, 2% AN2728 twice daily and 1% AN2898 plus 2% AN2728 twice daily for 6 weeks in up to 80...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

AN2898: Phase I data

In a vehicle-controlled, German Phase I trial in 20 healthy volunteers, AN2898 5% ointment applied daily to the skin under occlusive, adhesive patches for 4 consecutive days was well tolerated and demonstrated no irritant potential....
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

AN2898: Phase Ib started

Anacor began a double-blind, vehicle-controlled, German Phase Ib trial to evaluate topical AN2898 in 12 patients with chronic plaque psoriasis. Anacor Pharmaceuticals Inc., Palo Alto, Calif.   Product: AN2898   Business: Autoimmune   Molecular target: Phosphodiesterase-4...